[go: up one dir, main page]

GT201700246A - Métodos y kits para tratar la depresión - Google Patents

Métodos y kits para tratar la depresión

Info

Publication number
GT201700246A
GT201700246A GT201700246A GT201700246A GT201700246A GT 201700246 A GT201700246 A GT 201700246A GT 201700246 A GT201700246 A GT 201700246A GT 201700246 A GT201700246 A GT 201700246A GT 201700246 A GT201700246 A GT 201700246A
Authority
GT
Guatemala
Prior art keywords
kits
methods
treatment
depression
treat depression
Prior art date
Application number
GT201700246A
Other languages
English (en)
Inventor
Singh Jaskaran
CAERS Ivo
DALY Ella
Drevets Wayne
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of GT201700246A publication Critical patent/GT201700246A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)

Abstract

LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A, ENTRE OTRAS COSAS, MÉTODOS Y KITS PARA EL TRATAMIENTO DE LA DEPRESIÓN (PREFERENTEMENTE, DEPRESIÓN RESISTENTE AL TRATAMIENTO), O PARA EL TRATAMIENTO DE LA DEPRESIÓN EN UN PACIENTE SUICIDA Y/O PARA EL TRATAMIENTO Y/O PREVENCIÓN DE SUICIDIOS (POR EJEMPLO, PENSAMIENTOS SUICIDAS) QUE INCLUYEN LA ADMINISTRACIÓN DE ESKETAMINA DE CONFORMIDAD CON CIERTOS REGÍMENES DE DOSIS.
GT201700246A 2015-05-20 2017-11-16 Métodos y kits para tratar la depresión GT201700246A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20

Publications (1)

Publication Number Publication Date
GT201700246A true GT201700246A (es) 2019-07-29

Family

ID=57320901

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700246A GT201700246A (es) 2015-05-20 2017-11-16 Métodos y kits para tratar la depresión

Country Status (20)

Country Link
US (1) US20160338977A1 (es)
EP (1) EP3297618A4 (es)
JP (1) JP2018515557A (es)
KR (1) KR20180008634A (es)
CN (1) CN107735081A (es)
AU (3) AU2016263598A1 (es)
CA (1) CA2986477A1 (es)
CL (1) CL2017002904A1 (es)
CO (1) CO2017011564A2 (es)
DO (1) DOP2017000268A (es)
EA (1) EA201792545A1 (es)
EC (1) ECSP17077930A (es)
GT (1) GT201700246A (es)
HK (1) HK1252937A1 (es)
IL (1) IL255463A (es)
MA (1) MA42135A (es)
MX (1) MX2017014797A (es)
PE (1) PE20180260A1 (es)
PH (1) PH12017502103A1 (es)
WO (1) WO2016187491A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152196A1 (en) 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
WO2016025581A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
CA3086478A1 (en) * 2017-12-22 2019-06-27 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
US12036189B2 (en) * 2018-06-27 2024-07-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP3628313B1 (en) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Ketamine composition for use in a method of treatment of depression by pulmonary administration
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070706A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
US11865088B2 (en) * 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
WO2020075134A1 (en) * 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
IL318198A (en) * 2019-03-05 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP4021432A4 (en) * 2019-08-28 2023-08-16 Janssen Pharmaceuticals, Inc. ESKETAMIN FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regime with esketamine for treating major depressive disorder
CA3185137A1 (en) * 2020-05-28 2021-12-02 Janssen Pharmaceutica Nv Methods for treating depression
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
MX2014010939A (es) * 2012-03-12 2014-11-13 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
NZ713300A (en) * 2013-04-12 2020-05-29 Icahn School Med Mount Sinai Method for treating post-traumatic stress disorder
AU2015318123A1 (en) * 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression

Also Published As

Publication number Publication date
AU2016263598A1 (en) 2017-11-23
PH12017502103A1 (en) 2018-05-07
CL2017002904A1 (es) 2018-04-20
AU2021215155A1 (en) 2021-09-02
ECSP17077930A (es) 2018-02-28
EA201792545A1 (ru) 2018-05-31
CN107735081A (zh) 2018-02-23
MA42135A (fr) 2018-03-28
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
US20160338977A1 (en) 2016-11-24
KR20180008634A (ko) 2018-01-24
CO2017011564A2 (es) 2018-04-19
DOP2017000268A (es) 2018-04-15
IL255463A (en) 2018-01-31
WO2016187491A1 (en) 2016-11-24
JP2018515557A (ja) 2018-06-14
MX2017014797A (es) 2018-02-15
EP3297618A1 (en) 2018-03-28
EP3297618A4 (en) 2019-01-23
HK1252937A1 (zh) 2019-06-06
CA2986477A1 (en) 2016-11-24
PE20180260A1 (es) 2018-02-05

Similar Documents

Publication Publication Date Title
GT201700246A (es) Métodos y kits para tratar la depresión
MX388325B (es) Metodos de diagnostico para tratamiento con linfocitos t.
EA201792649A1 (ru) Способы кондиционирования пациентов для t-клеточной терапии
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112018008882A2 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
MX2017007256A (es) Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer.
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
BR112019008241A2 (pt) tratamento do prurigo nodular
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
DOP2017000121A (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson
MX2019003314A (es) Metodos de tratamiento de la elevacion de dominio 3 de inmunoglobulina de celula t y mucina (tim-3).
DOP2022000095A (es) Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax
AR097590A1 (es) Métodos para tratar el síndrome del x frágil y trastornos relacionados